- Home
- DSGN vs TERN Comparison
DSGN vs TERN Comparison
Compare DSGN & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- TERN
- Stock Information
- Founded
- DSGN 2017
- TERN 2017
- Country
- DSGN United States
- TERN United States
- Employees
- DSGN N/A
- TERN N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- DSGN Health Care
- TERN Health Care
- Exchange
- DSGN Nasdaq
- TERN Nasdaq
- Market Cap
- DSGN 224.8M
- TERN 263.8M
- IPO Year
- DSGN 2021
- TERN 2021
- Fundamental
- Price
- DSGN $3.91
- TERN $3.12
- Analyst Decision
- DSGN Hold
- TERN Buy
- Analyst Count
- DSGN 1
- TERN 5
- Target Price
- DSGN $4.00
- TERN $15.63
- AVG Volume (30 Days)
- DSGN 91.9K
- TERN 738.7K
- Earning Date
- DSGN 05-07-2025
- TERN 05-08-2025
- Dividend Yield
- DSGN N/A
- TERN N/A
- EPS Growth
- DSGN N/A
- TERN N/A
- EPS
- DSGN N/A
- TERN N/A
- Revenue
- DSGN N/A
- TERN N/A
- Revenue This Year
- DSGN N/A
- TERN N/A
- Revenue Next Year
- DSGN N/A
- TERN N/A
- P/E Ratio
- DSGN N/A
- TERN N/A
- Revenue Growth
- DSGN N/A
- TERN N/A
- 52 Week Low
- DSGN $2.60
- TERN $1.87
- 52 Week High
- DSGN $7.77
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- DSGN 53.86
- TERN 55.15
- Support Level
- DSGN $3.67
- TERN $3.01
- Resistance Level
- DSGN $4.13
- TERN $3.17
- Average True Range (ATR)
- DSGN 0.30
- TERN 0.18
- MACD
- DSGN 0.05
- TERN 0.01
- Stochastic Oscillator
- DSGN 85.78
- TERN 75.00
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.